Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter

AIDS

Volumn 13, Issue 7, 1999, Pages 851-858

  Revicki, Dennis A ^d   Moyle, Graeme ^a   Stellbrink, Hans Jurgen ^b   Barker, Chris ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Roche Global Pharmacoeconomic Res   (United States)

^d UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

AIDS; Combination antiretroviral therapy; Health related quality of life; HIV; Randomized clinical trials; Saquinavir; Zalcitabine; Zidovudine

Indexed keywords

CD4 ANTIGEN; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH STATUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; SAQUINAVIR; TREATMENT OUTCOME; ZALCITABINE; ZIDOVUDINE;

EID: 0032949639     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905070-00016     Document Type: Article

References (35)

1. 1. Carpenter CJ, Fischl MA, Hammer SM, et al.; Antiretroviral therapy for HIV infection in 1997. JAMA 1997, 277:1962-1969.
2. 2. BHIVA Guidelines Coordination Committee: British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997, 349:1086-1092.
3. 3. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors: a review for clinicians. JAMA 1997, 277:145-153.
4. 4. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
5. 5. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
6. 6. CAESAR Coordinating Committee: Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
7. 7. Haubrich R, Lalezari J, Follansbee FE, et al., and the NV14256 Study Team: Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998, 3:33-42.
8. 8. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C: Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
9. 9. Hammer SM, Squires KE, Hughes MD, et al: A controlled trial of two nucleoside analogs plus indinavir in persons human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
10. 10. Lenderking WR, Gelber RD, Cotton DJ, et al.: Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994, 330:738-743.
11. 11. DeBoer JB, van Dam FSAM, Sprangers MAG, et al.: Longitudinal study on the quality of life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-α. AIDS 1993, 7:947-953.
12. 12. Revicki DA, Brown RE, Henry DH, et al.: Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquired Immune Defic Syndr 1994, 7:474-484.
13. 13. Stanton DI, Wu AW, Moore RD, et al.: Functional status of persons with HIV infection in an ambulatory setting. J Acquired Immune Defic Syndr 1994, 7:1050-1056.
14. 14. Wu AW, Rubin HR, Mathews WC, et al.: Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. J Acquired Immune Defic Syndr 1993, 6:452-458.
15. 15. Revicki DA, Swartz C, Wu AW, Haubrich R, Collier AC: Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir-zalcitabine therapy for advanced HIV-infected adults with CD4 counts between 50 and 300 per cubic millimeter. Antiviral Ther 1999, in press.
16. 16. Cohen C, Revicki DA, Nabulsi A, et al.: A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. AIDS 1998, 12:1495-1502.
17. 17. Delta Coordinating Committee: Delta: a randomized double-blind controlled trial comparing combination of zidovudine + didanosine or zalcitabine with zidovudine alone in HIV-1 infected individuals. Lancet 1996, 348:283-291.
18. 18. Revicki DA: Health care technology assessment and health-related quality of life. In Health care technology and its assessment: an international perspective. Edited by Banta D, Luce BR. New York: Oxford University Press; 1993:114-131.
19. 19. Testa MA, Lenderking WR: Quality of life considerations in clinical trials of persons with HIV infection. In AIDS clinical trials. Edited by Finkelstein D, Schoenfeld D. New York: Wiley-Liss; 1995:213-241.
20. 20. Wu AW, Rubin HR, Mathews WC, et al.: A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 1991; 29:786-798.
21. 21. Revicki DA, Wu AW, Murray M: Change in clinical status, health status and health utility outcomes in HIV-infected patients. Med Care 1995, 33:A5173-5182.
22. 22. Wu AW, Revicki DA, Jacobson D, Malitz FE: Evidence for the reliability, validity and usefulness of the MOS-HIV Health Survey. Qual Life Res 1997, 6:481-493.
23. 23. Scott-Lennox JA, Wu AW, Boyer JG, Ware JE: Reliability and validity of French, German, Italian, Dutch, and UK English translations of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Med Care 1999, in press.
24. 24. Revicki DA, Sorensen S, Wu AW: Reliability and validity of physical and mental health summary scores from the MOS HIV Health Survey. Med Care 1998, 36:126-137.
25. 25. Kind P: The EuroQol instrument: an index of health-related quality of life. In Quality of life and pharmacoeconomics in clinical trials, 2nd ed. Edited by Spilker B. Philadelphia: Lippincott-Raven; 1996:191-201.
26. 26. Froberg DG, Kane RL: Methodology for measuring health-state preferences: II: scaling methods. J Clin Epidemiol 1989, 52:459-471.
27. 27. O'Brien PC: Procedures for comparing samples with multiple endpoints. Biometrics 1984, 40:1079-1087.
28. 28. Lehmacher W, Wassmer G, Reitmeir P: Procedures for two-sample comparisons with multiple endpoints controlling the experimentwise error rate. Biometrics 1991, 47:511-521.
29. 29. Lubeck DP, Fries JF: Health status among persons infected with human immunodeficiency virus: a community-based study. Med Care 1993, 31:269-276.
30. 30. Lubeck DP, Fries JF: Changes in quality of life among persons with HIV infection. Qual Life Res 1992, 1:359-366.
31. 3: a double-blind controlled trial. Antiviral Ther 1997, 2:229-236.
32. 32. Chan K, Revicki DA: Changes in surrogate laboratory markers, clinical endpoints and health-related quality of life in patients infected with the human immunodeficiency virus. Fval Health Professions 1998, 21:265-281.
33. 33. Testa MA, Lenderking WR, Fischer L, Revicki DA, Collier AC: Effects of combination therapy with saquinavir, zidovudine and zalcitabine on quality of life. Abstracts of the 11th International Conference on AIDS. Vancouver, BC, 7-12 July 1996 [abstract].
34. 34. Flexner C: HIV-protease therapy. N Engl J Med 1998, 338:1281-1292.
35. 35. The Department of Health and Human Services (DHHS) Panel on Clinical Practices for the treatment of HIV Infection: Guidelines for use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998, 128:1079-1100.